BOULDER, Colo., Aug. 9, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule cancer therapies, today reported results for its fourth quarter and full year of fiscal 2017 and provided an update on the progress of its key clinical development programs and new partnerships.
“With the NDAs filed for binimetinib and encorafenib, we look forward to working with the FDA and EMA as they review our applications,” said Ron Squarer, Chief Executive Officer.
